---
title: "GLP-1 Weight-Loss Projection Calculator | GLPMate"
url: https://glpmate.me/tools/weight-loss-projection
language: en
description: "Average weight loss from the STEP and SURMOUNT trials, applied to your starting weight. An illustration from trial averages — not a prediction. Results vary."
updated: 2026-07-24
---
Free tool · no signup

# GLP-1 weight-loss projection

Curious what the clinical-trial averages look like on your scale? Enter your weight and pick a medication to apply the STEP and SURMOUNT trial averages — an illustration, not a prediction.

**Track the real curve, not the average**

GLPMate charts your actual weight trend against your dose — so you can see your response, plateaus and all.

[ Download on the **App Store** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=tools-weight-loss-projection&adj_redirect_android=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_macos=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_windows=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235) [ GET IT ON **Google Play** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=tools-weight-loss-projection&adj_redirect_ios=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_macos=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_windows=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate)

**Read first:** this is an _illustrative average from clinical trials_, not a prediction for you and not a promise. In the trials, individual results ranged from little or no loss to more than 25%. GLPMate does not guarantee any outcome — treatment decisions are between you and your prescriber.

Your current weight

kg

Units

Medication & dose (trial average)

Trial-average result at ~72 weeks

72.4kg

At the **19.5%** average from SURMOUNT-1, a 90 kg start would reach about 72.4 kg — a loss of about 17.6 kg. Your result will differ.

_Avg. loss_ **17.6 kg**

_Avg. %_ **19.5%**

_Trial_ **SURMOUNT-1**

Averages are mean total body-weight change with lifestyle support, at the trial endpoint. They are not a personal forecast.

## Where these averages come from

The percentages are the mean weight change reported in the pivotal randomized trials — applied to your weight only to make the numbers relatable. They describe trial _populations_, not individuals.

Medication | Trial | Avg. weight change | Duration

**Wegovy 2.4 mg**

semaglutide | STEP 1 (NEJM 2021) | −14.9% | 68 wks

**Zepbound 5 mg**

tirzepatide | SURMOUNT-1 (NEJM 2022) | −15% | 72 wks

**Zepbound 10 mg**

tirzepatide | SURMOUNT-1 (NEJM 2022) | −19.5% | 72 wks

**Zepbound 15 mg**

tirzepatide | SURMOUNT-1 (NEJM 2022) | −20.9% | 72 wks

### Why your result will differ

Averages hide a wide spread. In SURMOUNT-1, roughly a third of participants on the higher doses lost 25% or more — while others lost far less. Real-world loss is frequently lower than trials because of side effects, dose interruptions and stopping early. The strongest lever you control is consistency: reaching your dose, eating enough protein, and tracking so you can catch problems early.

### It is not linear

Weight comes off fastest early and slows toward a plateau near the trial endpoint, with stalls and drops along the way. GLPMate's [weight trend](/glp-1-weight-tracker) smooths the daily noise so a normal plateau doesn't read as failure.

Sources: STEP 1 (Wilding et al., _NEJM_ 2021) — semaglutide 2.4 mg, −14.9% at week 68; SURMOUNT-1 (Jastreboff et al., _NEJM_ 2022) — tirzepatide 5/10/15 mg, −15.0/−19.5/−20.9% at week 72. Educational illustration only — not medical advice, not a prediction, and not a promise of results. Talk to your prescriber about what to expect.

## Related free tools

[ **Eligibility check** BMI and the clinical criteria, in plain language. Open tool → ](/tools/glp-1-eligibility-checker) [ **Titration planner** Your week-by-week dose schedule. Open tool → ](/tools/titration-planner) [ **Weight tracker** Chart your real trend against your dose. Learn more → ](/glp-1-weight-tracker)

This tool applies published clinical-trial **averages** to a weight you enter. It is for general education only — **not medical advice, not a diagnosis, not a prediction, and not a promise of any result.** Individual outcomes vary widely, including no weight loss.

GLPMate is an independent tracking app and does not guarantee outcomes. Wegovy® and Zepbound® are trademarks of their respective owners (Novo Nordisk, Eli Lilly); GLPMate is not affiliated with or endorsed by them. Discuss expected results and any treatment change with your prescriber.

## Sources

1. STEP 1 and STEP 4 trials (semaglutide 2.4 mg) ([STEP 1](https://doi.org/10.1056/NEJMoa2032183), [STEP 4](https://doi.org/10.1001/jama.2021.3224)) — published mean weight change
2. SURMOUNT-1 and SURMOUNT-4 trials (tirzepatide) ([SURMOUNT-1](https://doi.org/10.1056/NEJMoa2206038), [SURMOUNT-4](https://doi.org/10.1001/jama.2023.24945)) — published mean weight change

Last updated: 2026-07-24

FAQ

## Weight-loss questions

### How much weight do people lose on GLP-1 medications?

In the pivotal trials, adults averaged about 14.9% of body weight on semaglutide 2.4 mg (Wegovy, STEP 1) and 15–21% on tirzepatide 5–15 mg (Zepbound, SURMOUNT-1) over roughly 68–72 weeks, alongside diet and activity changes. These are averages — individual results ranged from little or no loss to more than 25%.

### Is this a prediction of what I will lose?

No. This applies a published trial average to your weight to make the scale relatable. It is not a personal prediction and not a promise. Your result depends on dose, adherence, diet, activity, sleep, other medications and your own biology — and some people respond much more or much less than the average.

### Why did trial participants lose more than some real-world users?

Trial participants reached and maintained the full dose with structured lifestyle support and close follow-up. Real-world results are often lower because of side effects, dose interruptions, cost-driven gaps or stopping early. Consistent tracking is one of the few things shown to help — which is exactly what GLPMate is for.

### How fast does the weight come off?

Loss is fastest in the first several months and slows as you approach a plateau near the trial endpoint. It is rarely linear — most people see stalls and whooshes along the way. GLPMate charts your real trend so a normal plateau does not feel like failure.

### What happens if I stop?

Trials (including STEP 4 and SURMOUNT-4) found that most people regain a substantial share of the lost weight after stopping, because the underlying appetite biology returns. GLP-1 therapy is generally long-term — discuss any change with your prescriber.

## See your own trend.

Free weight tracking. iOS & Android.

[ Download on the **App Store** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=tools-weight-loss-projection&adj_redirect_android=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_macos=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_windows=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235) [ GET IT ON **Google Play** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=tools-weight-loss-projection&adj_redirect_ios=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_macos=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_windows=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate)